KARYSS HEAD: Open Payments
NPI 1669125043 · LUBBOCK, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,846 in 58 payments from 18 companies in 2025. Trend: 2023 $1,144 · 2024 $736 · 2025 $2,846
Food & beverage: $2,846
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $544 |
| Lilly USA, LLC | 4 | $491 |
| ABBVIE INC. | 13 | $463 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $234 |
| AstraZeneca Pharmaceuticals LP | 3 | $174 |
| Kowa Pharmaceuticals America, Inc. | 9 | $149 |
| Dexcom, Inc. | 1 | $143 |
| GlaxoSmithKline, LLC. | 1 | $123 |
| Amgen Inc. | 1 | $123 |
| Phathom Pharmaceuticals, Inc. | 2 | $117 |
Products named: Wegovy, VRAYLAR, KISUNLA, Kerendia, QULIPTA, ZORYVE, AIRSUPRA, Dexcom G6 Transmitter.
Industry payments across TX — which companies pay providers there.
